Literature DB >> 1718594

Action of 2',2'-difluorodeoxycytidine on DNA synthesis.

P Huang1, S Chubb, L W Hertel, G B Grindey, W Plunkett.   

Abstract

The action of the new deoxycytidine analogue 2',2'-difluorodeoxycytidine (dFdC) on DNA synthesis was investigated in whole cells and in vitro assay systems with purified DNA polymerases. DNA synthesis in human lymphoblastoid CEM cells was inhibited by dFdC in a concentration-dependent manner that could not be reversed by exogenous deoxynucleosides. The analogue was incorporated into cellular DNA; most of the incorporated dFdC 5'-monophosphate (dFdCMP) residues were in internucleotide linkage. In vitro DNA primer extension assays demonstrated that dFdC 5'-triphosphate (dFdCTP) competed with deoxycytidine triphosphate for incorporation into the C sites of the growing DNA strand. The ratios of the apparent Km values for the incorporation of dFdCTP and dCTP into a C site of M13mp19 DNA were 21.8 and 22.9 for DNA polymerases alpha and epsilon, respectively. The apparent Ki values of dFdCTP were 11.2 microM for DNA polymerase alpha and 14.4 microM for polymerase epsilon. After dFdCMP incorporation, the primer was extended by one deoxynucleotide before a major pause in the polymerization process was observed. This was in contrast to the action of arabinosylcytosine 5'-triphosphate, which caused both DNA polymerases alpha and epsilon to pause at the site of incorporation. The 3'----5' exonuclease activity of DNA polymerase epsilon was essentially unable to excise nucleotides from DNA containing dFdCMP at either the 3'-end or at an internal position, whereas arabinosylcytosine monophosphate was removed from the 3'-terminus at 37% the rate for deoxynucleotides. The cytotoxic activity of dFdC was strongly correlated with the amount of dFdCMP incorporated into cellular DNA. Our results demonstrate qualitative and quantitative differences in the molecular actions of dFdC and arabinosylcytosine on DNA metabolism, but are consistent with an important role for such incorporation in the toxicity of dFdC.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1718594

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  202 in total

Review 1.  Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.

Authors:  S Noble; K L Goa
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

Review 2.  Gemcitabine in non-small cell lung cancer (NSCLC).

Authors:  C Manegold; P Zatloukal; K Krejcy; J Blatter
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

3.  Exploiting drug repositioning for discovery of a novel HIV combination therapy.

Authors:  Christine L Clouser; Steven E Patterson; Louis M Mansky
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

4.  Identification of Non-nucleoside Human Ribonucleotide Reductase Modulators.

Authors:  Md Faiz Ahmad; Sarah E Huff; John Pink; Intekhab Alam; Andrew Zhang; Kay Perry; Michael E Harris; Tessianna Misko; Suheel K Porwal; Nancy L Oleinick; Masaru Miyagi; Rajesh Viswanathan; Chris Godfrey Dealwis
Journal:  J Med Chem       Date:  2015-12-09       Impact factor: 7.446

Review 5.  ABC transporters and their role in nucleoside and nucleotide drug resistance.

Authors:  Yu Fukuda; John D Schuetz
Journal:  Biochem Pharmacol       Date:  2012-01-20       Impact factor: 5.858

6.  Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells.

Authors:  Partha Ray; Marcus A Cheek; Mariam L Sharaf; Na Li; Andrew D Ellington; Bruce A Sullenger; Barbara Ramsay Shaw; Rebekah R White
Journal:  Nucleic Acid Ther       Date:  2012-10       Impact factor: 5.486

7.  Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer.

Authors:  Xiaoqun Dong; Li Jiao; Yanan Li; Douglas B Evans; Huamin Wang; Kenneth R Hess; James L Abbruzzese; Donghui Li
Journal:  J Clin Oncol       Date:  2009-02-23       Impact factor: 44.544

8.  Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas.

Authors:  E S Casper; M R Green; D P Kelsen; R T Heelan; T D Brown; C D Flombaum; B Trochanowski; P G Tarassoff
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

9.  Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360).

Authors:  Godefridus J Peters; Kees Smid; Leonardo Vecchi; Ietje Kathmann; Dzjemma Sarkisjan; Richard J Honeywell; Nienke Losekoot; Osnat Ohne; Aric Orbach; Eran Blaugrund; Lak Shin Jeong; Young Bok Lee; Chang-Ho Ahn; Deog Joong Kim
Journal:  Invest New Drugs       Date:  2013-09-19       Impact factor: 3.850

10.  Alteration of the carbohydrate for deoxyguanosine analogs markedly changes DNA replication fidelity, cell cycle progression and cytotoxicity.

Authors:  Jessica J O'Konek; Brendon Ladd; Sheryl A Flanagan; Mike M Im; Paul D Boucher; Tico S Thepsourinthone; John A Secrist; Donna S Shewach
Journal:  Mutat Res       Date:  2010-01-08       Impact factor: 2.433

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.